RNAi therapeutics have shown great success with multiple US Food and Drug Administration (FDA)-approved products involving N-acetyl galactosamine (GalNAc)-conjugated siRNAs to treat liver-targeted ...

The flavonoid silymarin and one of its structural components, silibinin, are substances with documented hepatoprotective properties. Their mechanisms of action are still poorly understood. However ...

Silymarin is not soluble in water and is usually administered in capsules as a standard extract (70 to 80% silymarin). Silibinin and other components of silymarin are rapidly conjugated with ...